Format

Send to

Choose Destination
Arthritis Res Ther. 2017 Aug 17;19(1):191. doi: 10.1186/s13075-017-1396-8.

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.

Author information

1
Cleveland Clinic, Department of Rheumatic & Immunologic Diseases, Cleveland, OH, 44195, USA.
2
University of California San Diego, Division of Rheumatology, Allergy and Immunology, La Jolla, CA, 92093, USA.
3
Horizon Pharma, Lake Forest, IL, 60045, USA.
4
AMPEL BioSolutions, LLC, 250 W. Main Street, Charlottesville, VA, 22902, USA. peterlipsky@ampelbiosolutions.com.

Abstract

BACKGROUND:

To assess frequency and distribution of infusion reactions (IRs) in responders and nonresponders in randomized clinical trials (RCTs) of intravenous pegloticase and the utility of the National Institute of Allergy and Infectious Disease/Food and Allergy and Anaphylaxis Network (NIAID/FAAN) criteria for identifying anaphylaxis in subjects experiencing IRs.

METHODS:

IRs from two RCTs of pegloticase were evaluated and categorized as anaphylaxis, hypersensitivity, or other. Serum levels of tryptase and total hemolytic complement (CH50) were evaluated at the time of all IRs. Frequency of IRs by each category was evaluated in all subjects, responders or nonresponders to pegloticase.

RESULTS:

There were 113 IRs in 1695 infusions. Of the 113 IRs, 6 met criteria for anaphylaxis, 53 had one feature of anaphylaxis and were designated as "hypersensitivity", and 54 had no features and were designated "other". In subjects receiving pegloticase every 2 weeks (Q2w), a total of 852 infusions were administered and the IR frequency was 0.5% in responders and 9.7% in nonresponders. In subjects receiving pegloticase every 4 weeks (Q4w), a total of 846 infusions were given and the IR frequency was 2.6% in responders and 12.2% in nonresponders. There were no differences among the three categories of IRs with regard to clinical course or biochemical evidence of immune activation determined by CH50 or tryptase levels.

CONCLUSION:

IRs mostly occurred in nonresponders. NIAID/FAAN criteria for anaphylaxis did not identify pegloticase-related IRs as having a higher frequency of immune activation or a more severe course. The results are consistent with the conclusion that discontinuance of pegloticase if uric acid rises to >6 mg/dL will decrease the frequency of IRs.

KEYWORDS:

Anaphylaxis; Gout; Hypersensitivity; Pegloticase

PMID:
28818095
PMCID:
PMC5561590
DOI:
10.1186/s13075-017-1396-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center